LEIDEN, the Netherlands, March 07 / B3C newswire / -- MIMETAS, a leading company in the field of organ-on-a-chip-based disease models, announces that it has launched its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format. As part of its OrganoReady® product line, MIMETAS offers two organoid-based products: ASC-derived Colon1 and Kidney2 Organoid tubules.
“We are thrilled to offer this cutting-edge technology to the research community,” says Jos Joore, co-CEO of MIMETAS. “We’ve worked for several years to optimize these OrganoReady® organoid products. As a result, our early-access users will be the first in the world to have license-free access to ready-to-use, donor-relevant organoid tubules of consistent quality.”
MIMETAS has strategically collaborated with HUB Organoid Technology (HUB) since October 2019 to develop organoid models on a chip. HUB Organoids are derived directly from ASCs and do not require reprogramming or transforming stem cells, thus maintaining donor-specific properties. Combining the OrganoPlate®, MIMETAS’ proprietary microfluidic platform, with HUB organoid technology, organoids are grown as perfused 3D tubular structures that can be accessed on both apical and basal sides. The fully optimized OrganoReady® Colon Organoid and OrganoReady® Kidney Organoid products are ideal for applications such as mechanistic toxicology and drug-induced organ injury. With 64 organoids on a single plate, the models are amenable to medium- to high-throughput screening. In addition MIMETAS can develop any type of organoid model in the OrganoPlate® on request.
The launch comes at a strategic moment. Recently, the FDA Modernization Act 2.0 was signed by US president Joe Biden. The act advocates the use of innovative technologies such as organoids and Organ-on-a-Chip as alternatives to animal testing.
For high resolution please click the image.
About MIMETAS
MIMETAS (Leiden, The Netherlands) is a global leader in disease modeling using organ-on-a-chip technologies. Its proprietary OrganoPlate® platform enables the development and high-throughput screening of physiologically relevant disease models for drug discovery and development. The company offers its technology and expertise in therapy co-development projects, services, and off-the-shelf products. MIMETAS works with leading pharmaceutical and biotech companies worldwide to develop novel therapies against unsolved diseases. Founded in 2013 in Leiden, the Netherlands, MIMETAS has grown into a multinational company with operations in Europe, Asia, and the USA. To learn more about MIMETAS' disease modeling capabilities and its OrganoPlate® platform, visit www.mimetas.com.
Contact
MIMETAS BV
Jos Joore, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
References
1. Gijzen et al., 2021 Nature Protocols
2. Schutgens et al., 2019 Nature Biotechnology
Keywords: Animals; Models, Biological; Biological Assay; High-Throughput Screening Assays; Research; Laboratories; Lab-On-A-Chip Devices; Drug Discovery; Drug Development; Organoids; Adult Stem Cells; Kidney; Technology; Biotechnology; Netherlands
Published by B3C newswire